Antares Pharma Inc (NASDAQ:ATRS) Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction that occurred on Friday, March 31st. The shares were sold at an average price of $2.91, for a total transaction of $87,300.00. Following the completion of the sale, the director now owns 190,213 shares of the company’s stock, valued at $553,519.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Antares Pharma Inc (NASDAQ:ATRS) traded up 0.74% on Thursday, reaching $2.74. 284,008 shares of the company’s stock traded hands. Antares Pharma Inc has a one year low of $0.79 and a one year high of $3.10. The company’s 50-day moving average price is $2.72 and its 200 day moving average price is $2.21. The firm’s market cap is $425.36 million.
Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, March 14th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative net margin of 53.11% and a negative return on equity of 45.93%. The business had revenue of $14.20 million for the quarter, compared to the consensus estimate of $12.77 million. On average, equities analysts forecast that Antares Pharma Inc will post ($0.11) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Antares Pharma Inc (ATRS) Director Thomas J. Garrity Sells 30,000 Shares” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/04/20/thomas-j-garrity-sells-30000-shares-of-antares-pharma-inc-atrs-stock-updated.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new position in Antares Pharma during the fourth quarter valued at approximately $6,797,000. JW Asset Management LLC increased its position in Antares Pharma by 30.0% in the fourth quarter. JW Asset Management LLC now owns 1,092,830 shares of the specialty pharmaceutical company’s stock valued at $2,547,000 after buying an additional 252,205 shares in the last quarter. Kingdon Capital Management L.L.C. increased its position in Antares Pharma by 24.0% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 2,016,830 shares of the specialty pharmaceutical company’s stock valued at $4,699,000 after buying an additional 390,092 shares in the last quarter. Renaissance Technologies LLC increased its position in Antares Pharma by 6.9% in the fourth quarter. Renaissance Technologies LLC now owns 2,859,341 shares of the specialty pharmaceutical company’s stock valued at $6,662,000 after buying an additional 185,000 shares in the last quarter. Finally, Oxford Asset Management bought a new position in Antares Pharma during the fourth quarter valued at approximately $367,000. 33.60% of the stock is currently owned by institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.